These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35781057)

  • 1. Targeting NAAA counters dopamine neuron loss and symptom progression in mouse models of parkinsonism.
    Palese F; Pontis S; Realini N; Torrens A; Ahmed F; Assogna F; Pellicano C; Bossù P; Spalletta G; Green K; Piomelli D
    Pharmacol Res; 2022 Aug; 182():106338. PubMed ID: 35781057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7,8-dihydroxyflavone protects 6-OHDA and MPTP induced dopaminergic neurons degeneration through activation of TrkB in rodents.
    Luo D; Shi Y; Wang J; Lin Q; Sun Y; Ye K; Yan Q; Zhang H
    Neurosci Lett; 2016 May; 620():43-9. PubMed ID: 27019033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence.
    Avagliano C; Russo R; De Caro C; Cristiano C; La Rana G; Piegari G; Paciello O; Citraro R; Russo E; De Sarro G; Meli R; Mattace Raso G; Calignano A
    Pharmacol Res; 2016 Nov; 113(Pt A):276-289. PubMed ID: 27616549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the discovery of N-acylethanolamine acid amidase inhibitors.
    Bandiera T; Ponzano S; Piomelli D
    Pharmacol Res; 2014 Aug; 86():11-7. PubMed ID: 24798679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of cyanamides as potent and selective N-acylethanolamine acid amidase inhibitors.
    Malamas MS; Farah SI; Lamani M; Pelekoudas DN; Perry NT; Rajarshi G; Miyabe CY; Chandrashekhar H; West J; Pavlopoulos S; Makriyannis A
    Bioorg Med Chem; 2020 Jan; 28(1):115195. PubMed ID: 31761726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Acylethanolamine Acid Amidase contributes to disease progression in a mouse model of multiple sclerosis.
    Pontis S; Palese F; Summa M; Realini N; Lanfranco M; De Mei C; Piomelli D
    Pharmacol Res; 2020 Oct; 160():105064. PubMed ID: 32634582
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Piomelli D; Scalvini L; Fotio Y; Lodola A; Spadoni G; Tarzia G; Mor M
    J Med Chem; 2020 Jul; 63(14):7475-7490. PubMed ID: 32191459
    [No Abstract]   [Full Text] [Related]  

  • 8. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
    Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
    Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of β-lactams as N-Acylethanolamine Acid Amidase (NAAA) inhibitors: Synthesis and SAR study of new, potent N-O-substituted derivatives.
    Petracca R; Ponzano S; Bertozzi SM; Sasso O; Piomelli D; Bandiera T; Bertozzi F
    Eur J Med Chem; 2017 Jan; 126():561-575. PubMed ID: 27915171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
    Lee EY; Lee JE; Park JH; Shin IC; Koh HC
    Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Salicylic acid protects against chronic L-DOPA-induced 6-OHDA generation in experimental model of parkinsonism.
    Borah A; Mohanakumar KP
    Brain Res; 2010 Jul; 1344():192-9. PubMed ID: 20470760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
    Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
    Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI).
    Li Y; Zhou P; Hu T; Ren J; Xu Y; Qiu Y; Lu C; Li Y
    Eur J Pharmacol; 2021 Dec; 912():174561. PubMed ID: 34655598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antinociceptive effects of the N-acylethanolamine acid amidase inhibitor ARN077 in rodent pain models.
    Sasso O; Moreno-Sanz G; Martucci C; Realini N; Dionisi M; Mengatto L; Duranti A; Tarozzo G; Tarzia G; Mor M; Bertorelli R; Reggiani A; Piomelli D
    Pain; 2013 Mar; 154(3):350-360. PubMed ID: 23218523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Inflammatory Effects of Fucoxanthinol in LPS-Induced RAW264.7 Cells through the NAAA-PEA Pathway.
    Jin W; Yang L; Yi Z; Fang H; Chen W; Hong Z; Zhang Y; Zhang G; Li L
    Mar Drugs; 2020 Apr; 18(4):. PubMed ID: 32326173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
    McCoy MK; Martinez TN; Ruhn KA; Szymkowski DE; Smith CG; Botterman BR; Tansey KE; Tansey MG
    J Neurosci; 2006 Sep; 26(37):9365-75. PubMed ID: 16971520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
    Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
    J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of multifunctional tetramethylpyrazine nitrone on models of Parkinson's disease in vitro and in vivo.
    Guo B; Xu D; Duan H; Du J; Zhang Z; Lee SM; Wang Y
    Biol Pharm Bull; 2014; 37(2):274-85. PubMed ID: 24305623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acylethanolamine acid amidase (NAAA) inhibition decreases the motivation for alcohol in Marchigian Sardinian alcohol-preferring rats.
    Fotio Y; Ciccocioppo R; Piomelli D
    Psychopharmacology (Berl); 2021 Jan; 238(1):249-258. PubMed ID: 33037452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.